Table 2.
Medical history and clinical characteristics of patients with COVID-19.
| Variables | COVID-19 patients |
|---|---|
| Symptoms | |
| Dyspnea | 17 (89.5%) |
| Dry cough | 8 (42.1%) |
| Pneumonia | 15 (78.9%) |
| Fever | 11 (57.9%) |
| Myalgia | 1 (5.3%) |
| Home therapy | 15 (78.9%) |
| Antihypertensive/cardiovascular therapy | 12 (63.2%) |
| Anticoagulants | 3 (21.1%) |
| 5-Alpha reductase inhibitors | 1 (5.3%) |
| Anti-Psychotics/anxiolitics | 4 (26.4%) |
| Oral Hypoglicemic drugs/insuline | 2 (10.6%) |
| Hypouricemic drugs | 1 (5.3%) |
| Duration of hospitalization (days) | 26 ± 12 |
| Hospital therapy | |
| Hydroxychloroquine | 9 (47.4%) |
| Heparin | 2 (10.5%) |
| Diuretics | 1 (5.3%) |
| Anti-virals | 10 (52.6%) |
| Steroids | 2 (10.5%) |
| Antibiotics | 4 (21.0%) |
| Blood analysis at sampling day | |
| Anemia | 9 (47.4%) |
| Hyponatremia | 2 (10.5%) |
| Hypernatremia | 1 (5.3%) |
| PCR > 8 mg/l | 10 (52.6%) |
| Lymphocytopenia | 6 (31.6%) |
| Hyperkalemia | 1 (5.3%) |
| Hypokalemia | 2 (10.5%) |
| PCT > 0.15 ng/ml | 2 (10.5%) |
| LDH > 222 U/l | 1 (5.3%) |
| D-dimer > 0.5 mcg/ml | 4 (21.0%) |
| Ferritin > 307 mcg/l | 1 (5.3%) |
| Hypoalbuminemia | 1 (5.3%) |
| Neutrophilia | 1 (5.3%) |
| Creatinine > 1.3 mg/dl | 3 (15.8%) |
| Mean Sa 02 at admission | 91.9 ± 3.4% |
| Mean Sa 02 at sampling day | 94.4 ± 3.1% |
| Mean Sa 02 at discharge | 98.3 ± 0.6% |
| Bilateral conjunctivitis | 7 (36.8%) |
| Before admission | 3 (15.8%) |
| At admission | 4 (21.0%) |
| At discharge | 0 (0%) |
| Ventilation at sampling day | 8 (42.1%) |
| Invasive | 0 (0%) |
| Not invasive | 8 (42.1%) |
| Outcome | |
| Recovery | 7 (36.8%) |
| Death | 12 (63.2%) |